News Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy August 9, 2022 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Announces Key Organizational Changes in Transition to Clinically Focused CompanyNext →Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
